
Yun Zhong, PhD is a Director and BTIG Biotechnology Analyst, specializing in gene therapy, genetic medicine, targeted therapy, rare disease and hematology. Prior to BTIG, Dr. Zhong was a Biotech Equity Research Analyst at Berenberg Capital Markets. Previously, he was Director within Biotech Equity Research at Janney Montgomery Scott. Earlier in his career, Dr. Zhong was a Vice President within Biotech Equity Research at SunTrust Robinson Humphrey, and a Biotech Equity Research Associate at Cowen. He earned a PhD in molecular biology and neuroscience from Rockefeller University, and an MS in biophysical engineering and BS in biophysical engineering from Osaka University.
BackCoverage Area
Company | Ticker |
---|---|
Voyager Therapeutics, Inc. | VYGR |
Sarepta Therapeutics, Inc. | SRPT |
Magenta Therapeutics | MGTA |
uniQure NV | QURE |
AVROBIO | AVRO |
Rocket Pharmaceuticals | RCKT |
Amicus Therapeutics | FOLD |
Passage Bio | PASG |
Taysha Gene Therapies | TSHA |
Selecta Biosciences | SELB |
Mereo Biopharma | MREO |
Anavex Life Sciences | AVXL |
Freeline Therapeutics | FRLN |
Graphite Bio | GRPH |